Why Novo Nordisk Stock Popped Today

Source The Motley Fool

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another shot in the arm yesterday -- one that helped the stock dodge the market downturn entirely and end the day somewhat in the green. The same news that helped Novo stock out yesterday, moreover, is today turning into solid gains as Novo Nordisk stock rises 2.5% through 11 a.m. ET.

And what news was that, you ask?

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Novo Nordisk now has an Ozempic pill.

Novo Nordisk's big news day

Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday that Novo Nordisk "earlier this year" submitted to the Food and Drug Administration an application to approve an oral form of its semaglutide GLP-1 weight loss drug.

BioPharmaDive notes that Novo has already reported positive clinical results with the new GLP-1 pill, which showed patients losing as much as 15% of their body weight over the course of a 64-week phase 3 trial.

Is Novo Nordisk stock a buy?

Curiously, this is both good news and bad news for Novo Nordisk stock. On the good news front, it stands to reason that if Ozempic is already a popular product despite its requiring patients to repeatedly stick themselves in the stomach with needles, then an oral form of Ozempic, no more complicated than swallowing a pill, will be even more popular -- and help Novo Nordisk to continue dominating this market.

On the other hand, BioPharmaDive notes that the pill Novo wants FDA approval for contains 70 times as much semaglutide as injectable Ozempic. The journal points out that such a large increase in dosage will require an even larger increase in Novo's production capacity, which only recently reached a point at which it can satisfy the injectables market.

Long story short, Novo has a big opportunity here, but needs to grow if it's to make the most of it.

Should you invest $1,000 in Novo Nordisk right now?

Before you buy stock in Novo Nordisk, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $532,771!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $593,970!*

Now, it’s worth noting Stock Advisor’s total average return is 781% — a market-crushing outperformance compared to 149% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 21, 2025

Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Wall Street Giants Poised to Offer Spot Bitcoin and Ethereum TradingThe Securities and Exchange Commission (SEC) and Commodity Futures Trading Commission (CFTC) alluded to major exchanges being able to roll out spot Bitcoin (BTC) and Ethereum (ETH) trading.
Author  Beincrypto
10 hours ago
The Securities and Exchange Commission (SEC) and Commodity Futures Trading Commission (CFTC) alluded to major exchanges being able to roll out spot Bitcoin (BTC) and Ethereum (ETH) trading.
placeholder
Pound Sterling extends decline amid surging UK Bond yieldsThe Pound Sterling (GBP) extends losses and trades cautiously near an almost four-week low around 1.3370 against the US Dollar (USD) during the European trading session on Wednesday.
Author  FXStreet
10 hours ago
The Pound Sterling (GBP) extends losses and trades cautiously near an almost four-week low around 1.3370 against the US Dollar (USD) during the European trading session on Wednesday.
placeholder
US JOLTS Job Openings expected to edge slightly lower in JulyThe Job Openings and Labor Turnover Survey (JOLTS) will be released on Wednesday by the United States (US) Bureau of Labor Statistics (BLS).
Author  FXStreet
11 hours ago
The Job Openings and Labor Turnover Survey (JOLTS) will be released on Wednesday by the United States (US) Bureau of Labor Statistics (BLS).
placeholder
Silver Price Forecast: XAG/USD marks fresh 14-year highs near $41.00Silver price (XAG/USD) following its six-day winning streak, trading around $40.98 per troy ounce on Wednesday, the highest since September 2011.
Author  FXStreet
11 hours ago
Silver price (XAG/USD) following its six-day winning streak, trading around $40.98 per troy ounce on Wednesday, the highest since September 2011.
placeholder
2025 Hottest US IPO Week: Klarna, Gemini, Figure Set for “Triple Launch”According to Bloomberg, at least five companies are now pricing their U.S. initial public offerings (IPOs) for the week starting September 8.
Author  TradingKey
12 hours ago
According to Bloomberg, at least five companies are now pricing their U.S. initial public offerings (IPOs) for the week starting September 8.
goTop
quote